Gier Chad, Gilchrist Ian, Fordham Matthew, Riordan Luke, Milchan Ella, Patel Nidhi, Mojahedi Azad, Choudhury Sahana, Kits Tara, Cohen Regina, Doughtery Joseph, Reilly John P, Kalogeropoulos Andreas, Rahman Tahmid, Chen On
Stony Brook Heart Institute, Stony Brook University Hospital, Stony Brook, NY, United States.
Stony Brook Renaissance School of Medicine, Stony Brook, NY, United States.
Front Cardiovasc Med. 2024 Jan 25;11:1284562. doi: 10.3389/fcvm.2024.1284562. eCollection 2024.
Dyslipidemia is a leading contributor to atherosclerotic cardiovascular disease (ASCVD). There has been a significant improvement in the treatment of dyslipidemia in the past 10 years with the development of new pharmacotherapies. The intent of this review is help enhance clinicians understanding of non-statin lipid lowering therapies in accordance with the 2022 American College of Cardiology Expert Consensus Clinical Decision Pathway on the Role of Non-statin Therapies for LDL-Cholesterol Lowering. We also present a single-center experience implementing a systematic inpatient protocol for lipid lowering therapy for secondary prevention of ASCVD.
血脂异常是动脉粥样硬化性心血管疾病（ASCVD）的主要促成因素。在过去10年中，随着新药物疗法的发展，血脂异常的治疗有了显著改善。本综述的目的是根据2022年美国心脏病学会关于非他汀类药物降低低密度脂蛋白胆固醇作用的专家共识临床决策路径，帮助临床医生更好地理解非他汀类降脂疗法。我们还介绍了在单中心实施系统性住院患者血脂降低治疗方案以进行ASCVD二级预防的经验。
